research use only
Cat.No.S3839
| Related Targets | Dehydrogenase HSP Transferase P450 (e.g. CYP17) PDE phosphatase PPAR Vitamin Mitochondrial Metabolism Drug Metabolite |
|---|---|
| Other Carbohydrate Metabolism Inhibitors | 2-DG (2-Deoxy-D-glucose) Bromopyruvic acid (3-BP) Lonidamine Dorzagliatin LY2608204 Voglibose 4',7-Dimethoxy-5-Hydroxyflavone AZD1656 Nodakenetin Kaempferol-3-O-neohesperidoside |
| Molecular Weight | 163.17 | Formula | C6H13NO4 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 19130-96-2 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | duvoglustat, moranolin | Smiles | C1C(C(C(C(N1)CO)O)O)O | ||
|
In vitro |
DMSO
: 33 mg/mL
(202.24 mM)
Water : 33 mg/mL Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Targets/IC50/Ki |
α-glucosidase
(Cell-free assay) |
|---|---|
| In vitro |
1-Deoxynojirimycin (DNJ) up to 200 μmol/L does not influence survival of HUVECs. This compound behaves as an antioxidant, decreases ROS production, and delays cellular senescence.
|
| In vivo |
1-Deoxynojirimycin (DNJ) inhibits intestinal glucose absorption in intestine. This compound down-regulates intestinal SGLT1, Na+/K+-ATP and GLUT2 mRNA and protein expression. Pretreatment with this chemical (50 mg/kg) increases the activity, mRNA and protein levels of hepatic glycolysis enzymes (GK, PFK, PK, PDE1) and decreases the expression of gluconeogenesis enzymes (PEPCK, G-6-Pase), improves glucose tolerance in both normal and diabetic mice. It inhibits intestinal glucose absorption and accelerates hepatic glucose Metabolism by directly regulating the expression of proteins involved in glucose transport systems, glycolysis and gluconeogenesis enzymes. DNJ reduces oxidative stress in the liver and plasma in rodents.
|
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT01380743 | Completed | Pompe Disease |
Amicus Therapeutics |
October 31 2011 | Phase 2 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.